Trending

cost-effectiveness

NICE rejects BMS’ Zeposia MS pill in provisional guidance

NICE rejects BMS’ Zeposia MS pill in provisional guidance

NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing

X

NICE rejects BMS’ Zeposia MS pill in provisional guidance

https://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/

After two decades, NICE begins consultation on drug assessment methods

After two decades, NICE begins consultation on drug assessment methods

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how

X

After two decades, NICE begins consultation on drug assessment methods

https://pharmaphorum.com/news/nice-begins-consultation-on-cost-effectiveness-methods/

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said

X

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

https://pharmaphorum.com/news/nice-rejects-sanofis-cablivi-for-rare-blood-disorder-ttp/

Study sets benchmark for cost of repurposed coronavirus drugs

Study sets benchmark for cost of repurposed coronavirus drugs

Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for

X

Study sets benchmark for cost of repurposed coronavirus drugs

https://pharmaphorum.com/news/study-sets-benchmark-for-cost-of-repurposed-coronavirus-drugs/

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people

X

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

NICE rejects Roche’s Polivy combination in advanced lymphoma

NICE rejects Roche’s Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with

X

NICE rejects Roche’s Polivy combination in advanced lymphoma

https://pharmaphorum.com/news/nice-rejects-roches-polivy/

Child with rare disease takes NICE to court over access to life-changing therapy

Child with rare disease takes NICE to court over access to life-changing therapy

NICE’s decision-making process will come under legal scrutiny in court this week, after a child and her family

X

Child with rare disease takes NICE to court over access to life-changing therapy

https://pharmaphorum.com/news/child-with-rare-disease-takes-nice-to-court-over-access-to-life-changing-therapy/

UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMC

UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMC

Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available

X

UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMC

https://pharmaphorum.com/news/uks-nhs-to-fund-shionogis-mulpleo-after-backing-from-nice-and-smc/

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as

X

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

https://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com